Orphenadrine induces secondarily generalized convulsive status epilepticus in rats

Area of Science:

• Neuroscience
• Pharmacology
• Epilepsy Research

Background:

• Orphenadrine (ORPH) is an anticholinergic drug with potential convulsant properties.
• Understanding drug-induced seizures is crucial for developing effective antiepileptic treatments.
• Existing models for studying status epilepticus (SE) can be complex and time-consuming.

Purpose of the Study:

• To evaluate the convulsant potency of orphenadrine (ORPH) in rats.
• To screen conventional antiepileptic drugs (AEDs) for their efficacy in suppressing ORPH-induced seizures.
• To establish a novel, practical experimental model for studying SE pathophysiology and evaluating new AEDs.

Main Methods:

• Male Wistar rats received intraperitoneal injections of ORPH (50-80 mg/kg).
• Seizure latency, episode frequency, duration of status epilepticus (SE), and mortality were recorded with electroencephalographic (EEG) monitoring.
• The effects of established AEDs (carbamazepine, ethosuximide, phenytoin, valproate, diazepam, phenobarbital) on ORPH-induced seizures were assessed.

Main Results:

• ORPH induced dose-dependent seizures, achieving 100% incidence at 80 mg/kg.
• Seizures progressed from complex partial fits to generalized convulsive SE lasting approximately 2 hours.
• Valproate, diazepam, and phenobarbital significantly suppressed ORPH-induced seizures in a dose-dependent manner.
• Carbamazepine, ethosuximide, and phenytoin showed no significant anticonvulsant effect.

Conclusions:

• Orphenadrine (ORPH) reliably induces status epilepticus (SE) in rats, presenting a new, accessible experimental model.
• This ORPH-induced seizure model is suitable for investigating SE pathophysiology.
• The model can be utilized for screening the efficacy of novel antiepileptic drugs (AEDs).